Which has stronger earnings & valuation, GHRS or SRRK?

GH Research is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is GHRS or SRRK more profitable?

GH Research's return on equity of -19.36% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Scholar Rock N/A -163.52% -96.67%

Which has stronger valuation and earnings, COGT or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is COGT or GHRS more profitable?

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% GH Research N/A -19.36% -18.73%

Which has higher valuation & earnings, LNTH or GHRS?

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.45 $233.56M $4.15 25.40 GH Research N/A N/A -$48.26M -$0.92 N/A

Is LNTH or GHRS more profitable?

Lantheus has a net margin of 18.05% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 29.32% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% GH Research N/A -19.36% -18.73%

Which has better valuation & earnings, GHRS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is GHRS or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Belite Bio N/A -13.14% -12.88%

Which has stronger earnings & valuation, GHRS or CNTA?

GH Research is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A

Is GHRS or CNTA more profitable?

GH Research's return on equity of -19.36% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Centessa Pharmaceuticals N/A -60.37% -44.17%

GH Research (GHRS) Competitors

$25.35 -1.16 (-4.38%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$25.34 -0.01 (-0.02%)

As of 07/13/2026 07:43 PM Eastern

Compare

GHRS vs. SRRK, COGT, LNTH, BLTE, and CNTA

Should you buy GH Research stock or one of its competitors? MarketBeat compares GH Research with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GH Research include Scholar Rock (SRRK), Cogent Biosciences (COGT), Lantheus (LNTH), Belite Bio (BLTE), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does GH Research compare to Scholar Rock?

GH Research (NASDAQ:GHRS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

GH Research's return on equity of -19.36% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Scholar Rock	N/A	-163.52%	-96.67%

GH Research presently has a consensus price target of $40.38, indicating a potential upside of 59.27%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 2.38%. Given GH Research's higher possible upside, research analysts clearly believe GH Research is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

GH Research is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

56.9% of GH Research shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GH Research has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

In the previous week, Scholar Rock had 8 more articles in the media than GH Research. MarketBeat recorded 9 mentions for Scholar Rock and 1 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Scholar Rock's score of 0.02 indicating that GH Research is being referred to more favorably in the media.

Company	Overall Sentiment
GH Research	Very Positive
Scholar Rock	Neutral

Summary

GH Research and Scholar Rock tied by winning 7 of the 14 factors compared between the two stocks.

How does GH Research compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

GH Research's return on equity of -19.36% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
GH Research	N/A	-19.36%	-18.73%

56.9% of GH Research shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, GH Research has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

GH Research is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

In the previous week, Cogent Biosciences had 2 more articles in the media than GH Research. MarketBeat recorded 3 mentions for Cogent Biosciences and 1 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Cogent Biosciences' score of 1.60 indicating that GH Research is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Very Positive
GH Research	Very Positive

Cogent Biosciences presently has a consensus target price of $43.73, suggesting a potential upside of 16.73%. GH Research has a consensus target price of $40.38, suggesting a potential upside of 59.27%. Given GH Research's higher possible upside, analysts clearly believe GH Research is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

GH Research beats Cogent Biosciences on 8 of the 13 factors compared between the two stocks.

How does GH Research compare to Lantheus?

Lantheus (NASDAQ:LNTH) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lantheus had 3 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Lantheus' score of 1.19 indicating that GH Research is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantheus	Positive
GH Research	Very Positive

Lantheus currently has a consensus price target of $108.29, indicating a potential upside of 2.75%. GH Research has a consensus price target of $40.38, indicating a potential upside of 59.27%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.45	$233.56M	$4.15	25.40
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Lantheus has a net margin of 18.05% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 29.32% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
GH Research	N/A	-19.36%	-18.73%

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, GH Research has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Summary

Lantheus beats GH Research on 10 of the 14 factors compared between the two stocks.

How does GH Research compare to Belite Bio?

GH Research (NASDAQ:GHRS) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

56.9% of GH Research shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GH Research has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

GH Research currently has a consensus target price of $40.38, indicating a potential upside of 59.27%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 38.07%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Belite Bio had 1 more articles in the media than GH Research. MarketBeat recorded 2 mentions for Belite Bio and 1 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Belite Bio's score of 0.28 indicating that GH Research is being referred to more favorably in the media.

Company	Overall Sentiment
GH Research	Very Positive
Belite Bio	Neutral

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio's return on equity of -13.14% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Belite Bio	N/A	-13.14%	-12.88%

Summary

GH Research beats Belite Bio on 9 of the 13 factors compared between the two stocks.

How does GH Research compare to Centessa Pharmaceuticals?

GH Research (NASDAQ:GHRS) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

GH Research's return on equity of -19.36% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

GH Research is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

56.9% of GH Research shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GH Research currently has a consensus target price of $40.38, suggesting a potential upside of 59.27%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given GH Research's stronger consensus rating and higher probable upside, equities research analysts plainly believe GH Research is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, GH Research had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 1 mentions for GH Research and 0 mentions for Centessa Pharmaceuticals. GH Research's average media sentiment score of 1.89 beat Centessa Pharmaceuticals' score of 0.00 indicating that GH Research is being referred to more favorably in the media.

Company	Overall Sentiment
GH Research	Very Positive
Centessa Pharmaceuticals	Neutral

GH Research has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Summary

GH Research beats Centessa Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-27.55	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	5.62	8.49	10.75	6.29
Net Income	-$48.26M	$23.83M	$3.58B	$330.66M
7 Day Performance	-5.73%	-3.56%	-2.06%	-1.32%
1 Month Performance	20.03%	6.31%	3.32%	-0.64%
1 Year Performance	53.73%	48.30%	26.36%	19.08%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	3.3463 of 5 stars	$25.35 -4.4%	$40.38 +59.3%	+59.7%	$1.82B	N/A	N/A	10	Positive News
SRRK Scholar Rock	1.7123 of 5 stars	$57.44 +3.8%	$56.00 -2.5%	+46.1%	$6.88B	N/A	N/A	140
COGT Cogent Biosciences	2.1125 of 5 stars	$39.92 +1.2%	$43.73 +9.5%	+241.2%	$6.84B	N/A	N/A	80
LNTH Lantheus	3.0926 of 5 stars	$103.35 +0.5%	$101.86 -1.4%	+29.6%	$6.73B	$1.54B	24.91	1,193	Positive News
BLTE Belite Bio	3.3501 of 5 stars	$158.42 +2.9%	$203.00 +28.1%	+132.6%	$6.35B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. SRRK, COGT, LNTH, BLTE, and CNTA

How does GH Research compare to Scholar Rock?

Summary

How does GH Research compare to Cogent Biosciences?

Summary

How does GH Research compare to Lantheus?

Summary

How does GH Research compare to Belite Bio?

Summary

How does GH Research compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. SRRK, COGT, LNTH, BLTE, and CNTA

How does GH Research compare to Scholar Rock?

Is GHRS or SRRK more profitable?

Do analysts recommend GHRS or SRRK?

Which has stronger earnings & valuation, GHRS or SRRK?

Do institutionals & insiders hold more shares of GHRS or SRRK?

Which has more volatility and risk, GHRS or SRRK?

Does the media refer more to GHRS or SRRK?

Summary

How does GH Research compare to Cogent Biosciences?

Is COGT or GHRS more profitable?

Do institutionals & insiders have more ownership in COGT or GHRS?

Which has more risk & volatility, COGT or GHRS?

Which has stronger valuation and earnings, COGT or GHRS?

Does the media prefer COGT or GHRS?

Do analysts rate COGT or GHRS?

Summary

How does GH Research compare to Lantheus?

Do institutionals & insiders hold more shares of LNTH or GHRS?

Does the media prefer LNTH or GHRS?

Do analysts prefer LNTH or GHRS?

Which has higher valuation & earnings, LNTH or GHRS?

Is LNTH or GHRS more profitable?

Which has more risk and volatility, LNTH or GHRS?

Summary

How does GH Research compare to Belite Bio?

Do insiders and institutionals have more ownership in GHRS or BLTE?

Which has more risk and volatility, GHRS or BLTE?

Do analysts prefer GHRS or BLTE?

Does the media prefer GHRS or BLTE?

Which has better valuation & earnings, GHRS or BLTE?

Is GHRS or BLTE more profitable?

Summary

How does GH Research compare to Centessa Pharmaceuticals?

Is GHRS or CNTA more profitable?

Which has stronger earnings & valuation, GHRS or CNTA?

Do insiders & institutionals hold more shares of GHRS or CNTA?

Do analysts recommend GHRS or CNTA?

Does the media prefer GHRS or CNTA?

Which has more volatility & risk, GHRS or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools